Assenagon Asset Management S.A. Trims Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN)

Assenagon Asset Management S.A. decreased its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 83.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 56,617 shares of the company’s stock after selling 289,575 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.10% of Design Therapeutics worth $349,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Paloma Partners Management Co acquired a new stake in Design Therapeutics during the 3rd quarter worth $64,000. SG Americas Securities LLC acquired a new stake in shares of Design Therapeutics during the third quarter worth about $66,000. American Century Companies Inc. purchased a new position in shares of Design Therapeutics during the second quarter worth about $71,000. The Manufacturers Life Insurance Company acquired a new position in Design Therapeutics in the 3rd quarter valued at about $71,000. Finally, Cubist Systematic Strategies LLC raised its stake in Design Therapeutics by 75.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 23,497 shares of the company’s stock valued at $79,000 after acquiring an additional 10,113 shares during the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Design Therapeutics Stock Down 2.9 %

Shares of Design Therapeutics stock opened at $4.97 on Friday. The firm has a market cap of $281.40 million, a price-to-earnings ratio of -5.85 and a beta of 1.82. Design Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $7.77. The company’s 50-day simple moving average is $5.77 and its 200-day simple moving average is $5.33.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03. Equities research analysts anticipate that Design Therapeutics, Inc. will post -0.91 EPS for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.